BrainChild Bio, Inc.
BrainChild Bio develops CAR T-cell therapies for central nervous system tumors, prioritizing pediatric brain cancers such as diffuse intrinsic pontine glioma and extending its pipeline to adult tumors including glioblastoma and brain metastases. It aims to create safe and effective treatment options for children and adults with incurable brain tumors.
Facts
- Sectors
- Biotechnology Research
- Employees
- 11–50
- Stage
- Series A
- Founders
- Michael Jensen, MD
Is this your organization? Claim it
Founders
-
Michael Jensen Founder, Chief Scientific Officer
Executives
-
Steven Brugger Executive, Chief Executive Officer